Last reviewed 2026-04-23 · How we verify

AZD5423

AZD5423 is a small molecule inhibitor of the CD73 enzyme.

AZD5423 is a small molecule inhibitor of the CD73 enzyme. Used for Metastatic non-small cell lung cancer, PD-L1 positive.

At a glance

Mechanism of action

CD73 is an enzyme involved in the production of adenosine, which plays a role in immune suppression. By inhibiting CD73, AZD5423 aims to reduce adenosine levels and enhance anti-tumor immune responses.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive

Common side effects

• Nausea
• Diarrhea
• Fatigue

Key clinical trials

• The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen (PHASE2)
• A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways (PHASE1)
• Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects (PHASE1)
• A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways (PHASE1)
• AZD5423 Multiple Ascending Dose Study (PHASE1)
• AZD5423 Single Ascending Dose Study (PHASE1)
• Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.